Feature | May 13, 2014

Expert Consensus Statement Attempts To Close Gap On ICD Guidance for Specific Populations

May 13, 2014 — The Heart Rhythm Society (HRS), American College of Cardiology (ACC) and American Heart Association (AHA) released Expert Consensus Statement on the Use of Implantable Cardioverter Defibrillator Therapy in Patients Who Are Not Included or Not Well Represented in Clinical Trials at Heart Rhythm 2014, the 35th annual scientific sessions of HRS. The expert consensus statement provides first-of-its-kind guidance on ICD therapy for the management of patient populations who are not well represented in clinical trials and, as a result, not specifically included in existing guidelines.

ICDs have emerged as an important treatment option for patients who are at risk of sudden cardiac arrest, and are very effective for stopping life-threatening abnormal heart rhythms. However, while ICD therapy has been proven beneficial in many patient populations, there remain scenarios where clinicians are often asked to make decisions regarding ICD therapy for patients who fall outside of existing guidelines.

"Without exception, guidelines help clinicians make important decisions when it comes to ICD therapy; however, we must continue to refine our understanding of who benefits from ICD implantation in order to optimize patient care," said task force chair and lead author of the statement, Fred M. Kusumoto, M.D., FHRS, the Mayo Clinic in Jacksonville, Fla. "Because guidelines are mainly determined by the outcomes of large clinical trials, smaller patient populations or unique circumstances are typically not provided with indications for treatment. This document will serve as a new guide for clinicians so that many more, if not all, patients receive the right treatment at the right time."

The members of the writing group performed a comprehensive literature search, and then developed a series of recommendations with an explanation of the reasoning and research used to make each recommendation. The writing group also evaluated the available data on important situations for which ICD therapy might be beneficial in selected populations.

The expert consensus statement includes specific recommendations for the following four situations:

  1. Use of an ICD in patients with an abnormal troponin that is not due to a myocardial infarction (MI);
  2. Use of an ICD within 40 days after a MI;
  3. Use of an ICD within the first 90 days after revascularization; and
  4. Use of an ICD in the first nine months after initial diagnosis of nonischemic cardiomyopathy.

Additionally, the writing group evaluated the utility of an atrial lead in a patient requiring ICD therapy without cardiac resynchronization therapy (CRT). The statement provides recommendations for specific scenarios where CRT is not indicated or not desired and a clinician must decide between a single- or dual-chamber ICD. Specific scenarios, including but not limited to those with AV block, Long QT syndrome, and persistent or permanent AF, are outlined with atrial lead use noted as either recommended, not recommended, can be useful or may be considered.

The recommendations aim to help improve consistency and overall quality among hospitals and healthcare providers. Initiatives that standardize data elements and define best practices are critical for leveraging the benefits of ICD therapy to large populations. Future research should continue to evaluate the effectiveness and value of ICD therapy.

The consensus statement was developed in collaboration with and endorsed by the Heart Failure Society of America (HFSA) and the Society of Thoracic Surgeons (STS). It was endorsed by the European Heart Rhythm Association (EHRA), Asia Pacific Heart Rhythm Society (APHRS) and Latin American Society of Cardiac Pacing and Electrophysiology, and will be published in the July 2014 edition of HeartRhythm.

For more information: www.hrsonline.org

Related Content

Acutus Medical, AcQMap High Resolution Imaging and Mapping System, improvement over sCT

Image courtesy of Acutus Medical

News | EP Mapping and Imaging Systems| October 06, 2015
Acutus Medical, a global heart rhythm technology company, presented data that show the AcQMap High Resolution Imaging...
News | Heart Failure| October 02, 2015
Cyberonics Inc. announced results from the extension of the ANTHEM-HF clinical study (ENCORE Study). Results of the...
AtriCure, cryoFORM cryoablation probe, launch
Technology | Ablation Systems| October 02, 2015
AtriCure Inc. launched the cryoFORM cryoablation probe, which offers increased probe flexibility to adapt to a variety...
predicting arrhythmias, mcgill university, alternans patterns
News | EP Lab| September 28, 2015
Researchers have discovered how to predict some cardiac arrhythmias several steps before they even occur. It’s a...
ACC, atrial fibrillation registries, ablation, left atrial appendage occlusion procedures, LAAO Registry
News | Atrial Fibrillation| September 24, 2015
The American College of Cardiology (ACC) launched two new clinical registry programs in August to track real-world...
Biotronik, NORDIC ICD trial, defibrillation testing, DF testing, shock efficacy
News | Implantable Cardioverter Defibrillators (ICD)| September 24, 2015
Biotronik announced the publication of NORDIC ICD (NO Regular Defibrillation testing In Cardioverter-Defibrillator...
guideline, treating supraventricular tachycardia, ACC, AHA, HRS
News | EP Lab| September 23, 2015
A new guideline aimed at helping clinicians treat patients with supraventricular tachycardia, or a rapid heart rate,...
MedLumics, OCT, real-time assessment, catheter ablation, atrial fibrillation
Feature | EP Mapping and Imaging Systems| September 17, 2015
MedLumics has announced the completion of a successful single-case pre-clinical feasibility study of its optical...
Texas Cardiac Arrhythmia Institute, TCAI, first in United States, EpiAccess System, epicardial ablation

Image courtesy of EpiEP

News | Ablation Systems| September 15, 2015
The Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently became the first facility in the...
Medtronic, Evera, ICD, MR-conditional, MRI, FDA approval
Technology | Implantable Cardioverter Defibrillators (ICD)| September 14, 2015
Medtronic received the first U.S. Food and Drug Administration (FDA) approval for an implantable cardioverter...
Overlay Init